Affymetrix (NASDAQ: AFFX) and Digiliti Money (OTCMKTS:DGLT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Institutional and Insider Ownership

9.3% of Digiliti Money shares are held by institutional investors. 50.9% of Digiliti Money shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Affymetrix and Digiliti Money, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affymetrix 0 0 0 0 N/A
Digiliti Money 0 0 1 0 3.00

Digiliti Money has a consensus target price of $6.00, indicating a potential upside of 2,900.00%. Given Digiliti Money’s higher possible upside, analysts plainly believe Digiliti Money is more favorable than Affymetrix.

Earnings and Valuation

This table compares Affymetrix and Digiliti Money’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Affymetrix N/A N/A N/A $0.12 116.75
Digiliti Money $7.97 million 0.25 -$15.16 million N/A N/A

Affymetrix has higher revenue, but lower earnings than Digiliti Money.

Profitability

This table compares Affymetrix and Digiliti Money’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Affymetrix 4.24% 4.84% 2.97%
Digiliti Money -147.73% N/A -199.21%

Summary

Digiliti Money beats Affymetrix on 5 of the 8 factors compared between the two stocks.

About Affymetrix

Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.

About Digiliti Money

Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.

Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.